Cardio-HART FAQ
Everything you need to know about Cardio-HART and our AI-powered diagnostics.
Looking for answers about how Cardio-HART works, what conditions it detects, or how it integrates into clinical workflows?
This FAQ section provides clear, expert-backed information for general practitioners, cardiologists, and patients.
Cardio-HART is an AI-powered diagnostic system that detects heart failure, valve disease, arrhythmias, and other cardiac conditions—directly in primary care. By replacing inconclusive ECGs with comprehensive heart data, it helps reduce unnecessary echocardiographies, speeds up diagnosis, and improves outcomes.
Explore the questions below to better understand the science, technology, and real-world benefits of Cardio-HART.
General Questions
Cardio-HART combines advanced ECG signal analysis with AI-driven algorithms (programmes) to detect structural and functional heart abnormalities that would typically require echocardiography. It does this by analyzing multiple cardiac parameters beyond traditional ECG interpretation.
Cardio-HART can identify a range of heart conditions, including:
Left ventricular hypertrophy (LVH)
Heart failure with preserved ejection fraction (HFpEF), mid-range (HFmrEF), and reduced ejection fraction (HFrEF)
Valvular disease (e.g., aortic stenosis, mitral regurgitation)
Conduction abnormalities and arrhythmias
Cardio-HART is primarily designed for detecting acquired heart conditions, though in some cases, it may provide insights into congenital abnormalities if they have developed significant structural effects over time.
Clinical Validation & Accuracy
Yes. Cardio-HART has undergone extensive clinical validation, demonstrating high diagnostic agreement with echocardiography findings. A peer-reviewed study published in BMJ Open Heart confirms that Cardio-HART can identify key cardiac abnormalities—including heart failure and valve disease—directly in primary care, without the need for imaging.
📄 Read the full study in BMJ Open Heart
Cardio-HART has been validated in both controlled clinical trials and real-world primary care settings, ensuring its accuracy and practicality in daily medical practice.
Studies show that Cardio-HART maintains high diagnostic accuracy even in patients with multiple comorbidities, as it considers multiple cardiac parameters in its analysis.
Workflow & Implementation
Yes, Cardio-HART is designed for use in primary care. However, results can be shared with a cardiologist for further evaluation if needed.
Cardio-HART complements traditional tools by providing rapid, non-invasive insights at the point of care, reducing the need for immediate referrals while improving diagnostic efficiency.
Clinicians always have the final say in diagnosis. The AI provides recommendations, but the clinician can override results if needed based on patient history and clinical judgment.
Cardio-HART supports integration with major EHR systems via standard HL7 and FHIR protocols, ensuring seamless data flow.
Patient Outcomes & Impact
By identifying patients who do not require immediate echocardiography, Cardio-HART helps prioritise referrals, reducing wait times and healthcare costs.
While primarily designed for symptomatic patients, Cardio-HART can also be used in high-risk populations for early detection of subclinical conditions.
Cardio-HART provides deeper cardiac insights, allowing emergency clinicians to make more informed triage decisions and reduce delays in treatment.
Yes, the device is compatible with telemedicine workflows, enabling remote cardiac assessments and consultations.
Regulatory Approvals & Market Adoption
Yes. Cardio-HART is CE-certified as a medical device under European regulations. It meets stringent safety and performance standards, and is already in clinical use across multiple healthcare systems in Europe.
Cardio-HART has been recognised by regulatory bodies as an innovative, AI-powered cardiac diagnostic system. Its clinical validation and evidence-based methodology support its adoption in regulated healthcare environments, including the EU and other global markets.
Yes. In several regions, Cardio-HART assessments are already reimbursed or funded through public healthcare programmes or insurance partnerships. Broader adoption is underway as more funders recognize the value of early, accurate cardiac diagnostics in reducing unnecessary referrals and improving patient outcomes.
Technical & AI-Related Questions
AI enhances traditional ECG interpretation by recognising complex patterns associated with structural and functional heart diseases, providing more detailed insights than standard ECGs.
Yes, Cardio-HART provides clinicians with detailed reports explaining its findings, including confidence scores and supporting ECG metrics.
Cardio-HART’s AI has been trained on diverse, multi-ethnic datasets to minimise biases and improve accuracy across different populations.
Business & Cost-Related Questions
Cardio-HART follows a hybrid pricing model. The diagnostic system is acquired through a one-off device purchase, followed by an annual software subscription. This ensures continued access to AI-powered analysis, system updates, and clinical support. From the second year onward, only the subscription is renewed—making it a scalable solution for long-term use in clinical environments.
Hospitals and clinics can expect reduced diagnostic costs, fewer unnecessary referrals, and improved patient outcomes, leading to a high ROI.
Yes, it is designed for use in both large hospitals and smaller clinics, requiring minimal set-up and training.